TOP TEN perturbations for 38611_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38611_at
Selected probe(set): 206606_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38611_at (206606_at) across 6674 perturbations tested by GENEVESTIGATOR:
RAF1 depletion study 1 / mock transfected SW-480 cell sample
Relative Expression (log2-ratio):4.262274Number of Samples:6 / 6
Experimental | RAF1 depletion study 1 |
RNAi-mediated gene knockdown of RAF1 in colorectal cancer cell line SW-480. | |
Control | mock transfected SW-480 cell sample |
SW-480 colorectal cell line sample transduced with non-targeting pLKO_NonTarget vector. |
RAF1 depletion study 1 / control vector transfected SW-480 cell sample
Relative Expression (log2-ratio):3.8948288Number of Samples:6 / 6
Experimental | RAF1 depletion study 1 |
RNAi-mediated gene knockdown of RAF1 in colorectal cancer cell line SW-480. | |
Control | control vector transfected SW-480 cell sample |
SW-480 colorectal cell line sample transduced with empty vector pLKO. |
expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) / expO kidney cancer study 1 (neoplasm, malignant; primary)
Relative Expression (log2-ratio):-3.283887Number of Samples:3 / 2
Experimental | expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) |
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid. | |
Control | expO kidney cancer study 1 (neoplasm, malignant; primary) |
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm. |
expO kidney cancer study 1 (neoplasm, malignant; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)
Relative Expression (log2-ratio):3.1762037Number of Samples:2 / 4
Experimental | expO kidney cancer study 1 (neoplasm, malignant; primary) |
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm. | |
Control | expO kidney cancer study 1 (granular cell carcinoma; primary) |
Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma. |
SW620 / SW480
Relative Expression (log2-ratio):2.694727Number of Samples:62 / 63
Experimental | SW620 |
Human metastatic cancer cell line derived from the lymph node of a patient with adenocarcinoma of the colon. Synonyms:SW-620; SW 620; SW.620 Cellosaurus code: | |
Control | SW480 |
Human primary cancer cell line derived from the colon of a male patient with adenocarcinoma. Synonyms:SW-480; SW 480; SW480E Cellosaurus code: |
expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) / expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.6820965Number of Samples:3 / 22
Experimental | expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) |
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid. | |
Control | expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the kidney of patients with papillary adenocarcinoma (NOS). |
colchicine study 7 (4000uM) / vehicle (medium) treated hepatocyte sample
Relative Expression (log2-ratio):-2.6798687Number of Samples:2 / 2
Experimental | colchicine study 7 (4000uM) |
Hepatocytes treated with compound: colchicine (4000uM; CHEMBL107) for 24 hours. ATC code: | |
Control | vehicle (medium) treated hepatocyte sample |
Hepatocytes treated with vehicle (medium) for 24 hours. |
expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)
Relative Expression (log2-ratio):2.5744133Number of Samples:22 / 4
Experimental | expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary) |
Primary tumor tissue samples obtained from the kidney of patients with papillary adenocarcinoma (NOS). | |
Control | expO kidney cancer study 1 (granular cell carcinoma; primary) |
Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma. |
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (7500 uM; HepaRG) / vehicle (DMSO) treated HepaRG cell sample
Relative Expression (log2-ratio):-2.5700693Number of Samples:3 / 12
Experimental | 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone study 1 (7500 uM; HepaRG) |
HepaRG cells exposed to 7500 uM 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (dissolved in 0.5% v/v DMSO) for 72 hours. Cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Chemical was added at day 19 of cultivation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:--- | |
Control | vehicle (DMSO) treated HepaRG cell sample |
HepaRG cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Firstly, cells were cultivated in DMSO-containing medium between days 13 - 19 to allow them to differentiate into hepatocyte-like cells and become fully functional. Then the vehicle was added. |
HCC study 9 (alcohol; HBV) / HCC study 9 (HBV)
Relative Expression (log2-ratio):2.5526972Number of Samples:3 / 10
Experimental | HCC study 9 (alcohol; HBV) |
Liver tissue biopsy sample from patients with alcohol abuse and Hepatitis B infection related hepatocellular carcinoma (HCC) after resection. | |
Control | HCC study 9 (HBV) |
Liver tissue biopsy sample from patients with Hepatitis B infection related hepatocellular carcinoma (HCC) after resection. |